patent.fyi
Applications  /  US 2026/0355212
United States Patent Application Publication

US 2026/0355212 A1

Published
Nov 12, 2026
Filed
Sep 12, 2023
Earliest date on the face
Sep 13, 2022
Classification
A61K 31/55
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Phenyl terminal group

What ifWhat if R1 used a directly attached phenyl ring to provide a rigid hydrophobic surface?
Claim language“—C0-6alkylene-(saturated cycloalkyl)”

A single bond joins the phenyl ring to the scaffold at R1. The planar aromatic ring presents a hydrophobic face and fixes the relative positions of its ring carbons.

1.4Carboxamide at the attachment site

What ifWhat if a carboxamide at R10 provided a polar contact?
Claim language“R10 is halo, CN”

The ring bonds directly to the carbonyl carbon of a primary carboxamide. The carbonyl oxygen accepts a hydrogen bond, and the amide nitrogen donates one.

1.9Spiro ether ring

What ifWhat if the two groups on the shared carbon closed into a four-membered ether ring?
Claim language“form a C3-C6cycloalkyl”

A methylene group extends from each side of the shared carbon, and an oxygen joins the two methylene groups. The resulting ring constrains the two attachment vectors and presents an ether oxygen as a hydrogen-bond acceptor.

1.10Double bond between adjacent carbons

What ifWhat if a double bond between neighboring framework carbons fixed their geometry without an R3–R5 ring closure?
Claim language“R3 and R5 together with the carbon atoms”

The carbon–carbon double bond fixes the two carbons and their directly bonded neighbors in one plane. The π bond restricts rotation about that connection.

1.12Fused nitrogen ring pair

What ifWhat if the pyrrolidine shared an edge with a cyclopropane ring to restrict its shape?
Claim language“a bridged 6 to 8 membered heterocycloalkyl”

One methylene group bonds to two adjacent pyrrolidine carbons to form a fused cyclopropane. The shared carbon–carbon edge constrains the geometry at both fusion atoms while retaining the pyrrolidine nitrogen.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Component substitution

Free form in a polymer dispersion

An amorphous dispersion of the inhibitor in its free form replaces the salt form in an oral dosage formulation. The free form and hydroxypropyl methylcellulose acetate succinate are dissolved in a common solvent and spray-dried to form a powder. Powder X-ray diffraction checks for crystalline material, and liquid chromatography measures drug release in a dissolution test.

Parameter or scale variation

Dissolution testing at two agitation rates

A paddle dissolution apparatus holds identical inhibitor tablets in separate vessels containing 900 mL of the same dissolution medium at 37 °C. One set of paddles rotates at 50 rpm and a second set rotates at 75 rpm. Samples taken at 5, 15, 30, and 60 minutes are filtered and assayed by liquid chromatography to compare release profiles.

Combination with existing systems

Unit dose packaging with moisture monitoring

Solid inhibitor doses are sealed individually in aluminum laminate blister cavities. The blister cards are enclosed in a sealed secondary pouch with a humidity indicator card visible through a clear barrier window. The indicator records moisture exposure within the pouch, and tablets from a matched stability sample are assayed for drug content and degradation products.

Solid form mapping in compressed tablets

A confocal Raman microscope maps a dry-polished cross section of a compressed inhibitor tablet. The instrument collects reference spectra from the inhibitor solid forms and the excipients, then acquires spectra on a grid across the cross section. Software matches each grid spectrum to the references and plots the locations of the identified solid forms.

Automated or data-driven variant

Automated quantitation of inhibitor degradation products

A liquid chromatography system analyzes formulation samples alongside a reference solution and a formulation blank. Software aligns peaks against reference retention times, integrates peak areas, and calculates concentrations for degradation products with calibration curves. The software flags unresolved peaks and reports their retention times and areas for review.

Specific version of a part

Paired ether oxygen acceptors

A six-membered terminal ring contains ether oxygens at positions 1 and 4. Both oxygens act as hydrogen-bond acceptors, and the ring fixes their spacing along the bond network.

Two substituent positions

Set p to 2. In the R1 arrangement indexed by p, place an RA group at each of two distinct positions.

One indexed substituent position

Set m to 1 in the R10-bearing arrangement. One position carries an R10 group.

Methoxy at R11

Use methoxy, —OCH3, for R11. The oxygen bonds directly to the framework and to a single methyl carbon.

Fluorine and hydroxyl substitutions

Set R3 to fluorine, R4 to hydroxyl, and R5 to hydrogen. The hydroxyl provides a hydrogen-bond donor and acceptor at the R4 position.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 8,466,148 B2
Published
Jun 18, 2013
Filed
Nov 7, 2011
Class
A61K 31/5377
Document BUS 8,933,074 B2
Published
Jan 13, 2015
Filed
Jun 17, 2013
Class
C07D 401/12
Claim 1
Document A
Document B
1.1R1 is (a) —C1-6alkyl, (b) —C1-6haloalkyl, (c) —C1-6alkylene-NHCO—C1-6haloalkyl, (d) —C0-6alkylene-(saturated cycloalkyl), (e) —C0-6alkylene-heterocycloalkyl, (f) —C0-6alkylene-(tricyclic heteroaryl), (g) -heteroarylene-cycloalkyl, (h) -heteroarylene-aryl, (i) wherein RA is halo, —OH, —CN, —NH2, —NO2, —C1-6alkyl, alkenyl, —C1-6alkoxy, —C1-6haloalkyl, —O—C0-6alkylene-aryl, aryl, cycloalkyl, heterocycloalkyl, or heteroaryl
X is selected from C3-C8 alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;
A · US 8,466,148 B2 · ¶ 14
X is selected from C3-C8 alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;
B · US 8,933,074 B2 · ¶ 13
1.2p is 0, 1, 2, 3, 4, or 5
1.3q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11
1.4(j) wherein R10 is halo, CN, —C1-6alkyl, —C1-6haloalkyl, —O(C1-6 branched alkyl), or —SO2(C1-6alkyl)
In an additional embodiment, Z is selected from benzimidazolyl, quinolinyl, tetrahydroquinolyl, imidazo[1,2-a]pyridin-2-yl, tetrahydroisoquinolyl, 5-methylpyridin-2-yl, 3,5-dimethylpyridin-2-yl, 6-fluoroquinolyl and isoquinolinyl, all of which may be optionally substituted with up to 3 substituents independently selected from alkyl, alkoxy, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, cycloalkylalkoxy, halogen, alkylsulfonyl and cyano and nitro.
A · US 8,466,148 B2 · ¶ 176
In an additional embodiment, Z is selected from benzimidazolyl, quinolinyl, tetrahydroquinolyl, imidazo[1,2-a]pyridin-2-yl, tetrahydroisoquinolyl, 5-methylpyridin-2-yl, 3,5-dimethylpyridin-2-yl, 6-fluoroquinolyl and isoquinolinyl, all of which may be optionally substituted with up to 3 substituents independently selected from alkyl, alkoxy, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, cycloalkylalkoxy, halogen, alkylsulfonyl and cyano and nitro.
B · US 8,933,074 B2 · ¶ 168
1.5m is 0, 1, or 2
1.6or (k) or wherein R11 is halo, CN, —C1-6alkyl, —C1-6haloalkyl, —C1-6alkoxy, or —SO2(C1-6alkyl)
In an additional embodiment, Z is selected from benzimidazolyl, quinolinyl, tetrahydroquinolyl, imidazo[1,2-a]pyridin-2-yl, tetrahydroisoquinolyl, 5-methylpyridin-2-yl, 3,5-dimethylpyridin-2-yl, 6-fluoroquinolyl and isoquinolinyl, all of which may be optionally substituted with up to 3 substituents independently selected from alkyl, alkoxy, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, cycloalkylalkoxy, halogen, alkylsulfonyl and cyano and nitro.
A · US 8,466,148 B2 · ¶ 176
In an additional embodiment, Z is selected from benzimidazolyl, quinolinyl, tetrahydroquinolyl, imidazo[1,2-a]pyridin-2-yl, tetrahydroisoquinolyl, 5-methylpyridin-2-yl, 3,5-dimethylpyridin-2-yl, 6-fluoroquinolyl and isoquinolinyl, all of which may be optionally substituted with up to 3 substituents independently selected from alkyl, alkoxy, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, cycloalkylalkoxy, halogen, alkylsulfonyl and cyano and nitro.
B · US 8,933,074 B2 · ¶ 168
1.7r is 0 or 1
1.8R3, R4, and R5 are each independently —H, halo, —OH, —CN, —NH2, —NO2, alkylenyl, —C1-6alkyl, —C1-6alkoxy, —C1-6haloalkyl, —O—C0-6alkylene-aryl, aryl, cycloalkyl, heterocycloalkyl, or heteroaryl
R3 and R4 are independently selected from C1-C4 alkyl, CF3, optionally substituted cycloalkyl, or R3 and R4 taken together form a 3-6 membered cycloalkyl ring;
A · US 8,466,148 B2 · ¶ 14
R3 and R4 are independently selected from C1-C4 alkyl, CF3, optionally substituted cycloalkyl; or R3 and R4 taken together form a 3-6 membered cycloalkyl ring;
B · US 8,933,074 B2 · ¶ 13
1.9or R3 and R4 together with the carbon atom to which they are attached, form a C3-C6cycloalkyl
R3 and R4 are independently selected from C1-C4 alkyl, CF3, optionally substituted cycloalkyl, or R3 and R4 taken together form a 3-6 membered cycloalkyl ring;
A · US 8,466,148 B2 · ¶ 14
R3 and R4 are independently selected from C1-C4 alkyl, CF3, optionally substituted cycloalkyl; or R3 and R4 taken together form a 3-6 membered cycloalkyl ring;
B · US 8,933,074 B2 · ¶ 13
1.10or R3 and R5 together with the carbon atoms to which they are attached, form a C3-C6cycloalkyl
1.11or R4 and R5 together with the carbon atoms to which they are attached, form a C3-C6cycloalkyl
1.12R2 is H or R2 and R3 together with the carbon atoms to which they are attached, form a C3-C6cycloalkyl or R2 and R5 together with the pyrrolidine ring to which they are attached form a bridged 6 to 8 membered heterocycloalkyl R6 is R7 and R are each independently H or C1-6alkyl n is 1, 2, or 3 wherein at each occurrence, cycloalkyl, saturated cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each independently substituted with 0, 1, 2, 3, or 4 substituents independently selected from the group consisting of halo, —OH, —CN, —NH2, —NH(C1-6alkyl), —N(C1-6alkyl)2, —NO2, —C1-6alkyl, —C1-6haloalkyl, —C1-6alkoxy, —SO2(C1-6alkyl), and —CO(C1-6alkyl) provided that where n is 1 R2, R7, and R8 are H R3 and R5 or R4 and R5 together with the carbon atom to which they are attached form a 3 membered or 5 membered-cycloalkyl then R1 is not
R5 is selected from alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl and optionally substituted alkoxyalkyl; n is independently selected from 1 and 2;
A · US 8,466,148 B2 · ¶ 14
R5 is selected from alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl and optionally substituted alkoxyalkyl; n is independently selected from 1 and 2; R7 is selected from hydrogen, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl and optionally substituted alkoxyalkyl;
B · US 8,933,074 B2 · ¶ 13

An empty cell means only that no passage was reproduced there.

Statements in these documents
The disclosure also relates to methods for treating neurological, neurodegenerative and psychiatric disorders including but not limited to those comprising cognitive deficits or schizophrenic symptoms.
A · US 8,466,148 B2 · ¶ 2
This experiment lends support to the use of a PDE10 inhibitor as an antipsychotic since similar trends are seen with known, marketed antipsychotics.
A · US 8,466,148 B2 · ¶ 8
The disclosure also relates to methods for treating neurological, neurodegenerative and psychiatric disorders including but not limited to those comprising cognitive deficits or schizophrenic symptoms.
B · US 8,933,074 B2 · ¶ 2
This experiment lends support to the use of a PDE10 inhibitor as an antipsychotic since similar trends are seen with known, marketed antipsychotics.
B · US 8,933,074 B2 · ¶ 8
Cite aspatent.fyi, US 2026/0355212 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355212/, SHA-256 de486745bcaa7bbd4094f45fc24ebe42095b5206ae3e7640d23ed194d6054eb3
First published
Permanent addresshttps://patent.fyi/US20260355212/
Content fingerprint (SHA-256)de486745bcaa7bbd4094f45fc24ebe42095b5206ae3e7640d23ed194d6054eb3
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi